Advances in the understanding of gut hormone physiology– particularly their role in appetite regulation, metabolism, and glucose homeostasis - have driven the development of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) as effective and safe treatments for type 2 diabetes (T2D) and obesity. This evidence concerns the gene GLP1R and obesity disorder.